Glenmark’s novel monoclonal antibody GBR 830 to enter phase II clinical studies Sanjiv Das Sep 3, 2015 GBR 830 targets activated T cells, which drives the pathology in most autoimmune diseases including rheumatoid arthritis, multiple…
